Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

133.22 +0.80 (+0.60%)
Streaming Delayed Price Updated: 3:58 PM EDT, Sep 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 594,313
Open 132.81
Bid (Size) 133.18 (2)
Ask (Size) 133.26 (1)
Prev. Close 132.42
Today's Range 132.45 - 136.60
52wk Range 117.64 - 169.98
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Japan Is Inching Toward Cannabis Legalization, Companies Like This One Could Benefit
A Japanese health ministry panel recommended that marijuana-derived medicines be treated the same as pharmaceuticals, reported Bloomberg. The expert panel, convened on Thursday, recommended a revision... 
Via Benzinga
UBS Slashes PT On This Stock By Over 89%? Plus Evercore ISI Group Predicts $150 For First Solar
Evercore ISI Group boosted First Solar, Inc. (NASDAQ: FSLR) price target from $88 to $150. First Solar shares rose 1.7% to $138.49 in pre-market trading. 
Via Benzinga

Performance

YTD
+1.46%
+1.46%
1 Month
-12.44%
-12.44%
3 Month
-14.61%
-14.61%
6 Month
-14.42%
-14.42%
1 Year
+1.21%
+1.21%

More News

Read More
5 Analysts Have This to Say About Jazz Pharmaceuticals
Via Benzinga
7 Top-Rated Biotech Stocks to Buy for Q4
Via InvestorPlace
The Bright Future Of Cannabis Isn’t In Dispensaries - It’s In The Biotech Lab
Via Talk Markets
Jazz Pharmaceuticals' Return On Capital Employed Insights
Via Benzinga
'Street Underestimates Jazz Pharma's Cash-Flow' Says This Analyst
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Jazz' Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures
Via Benzinga
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Via Investor Brand Network
Exposures Product Safety
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
Via FinancialNewsMedia
Exposures Product Safety
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
7 Biotech Stocks to Buy for Q3
Via InvestorPlace
Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread
Via Investor's Business Daily
Cannabis Stocks Struggle Through Q2 2022
Via Talk Markets
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
Via Benzinga
Brazilian Fund Invests $19M In US Cannabis Stocks
Via Benzinga
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
Via Benzinga
Jazz Pharmaceuticals' Late-Stage Multiple Sclerosis Study Misses Primary Endpoint
Via Benzinga
Jazz Pharma's Cannabidiol Mixture Spray Misses Primary Goal In Multiple Sclerosis Spasticity
Via Benzinga
Switzerland Removes Medical Marijuana Access Limitations As Demand Rises
Via Benzinga
This Pharmaceutical Company Is Moving Beyond CBD
Via Benzinga
Leisuretown: Diplo And Rob Dyrdek's New Cannabis Seltzers Launch In California Via Agreement With HERBL
Via Benzinga
4 Analysts Have This to Say About Jazz Pharmaceuticals
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.